2,4-thiazolidinedione has been researched along with Hyperglycemia in 20 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight." | 4.93 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. ( Ojo, O, 2016) |
| "The proposed novel type 2 diabetes subgroups provide an interesting concept that could lead to a better understanding of the pathophysiology of the broad group of type 2 diabetes, paving the way for personalised treatment choices based on understanding the root cause of the disease." | 2.72 | Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? ( Erazo-Tapia, E; Oscarsson, J; Schrauwen, P; Veelen, A, 2021) |
| "Insulin resistance is a fundamental feature of type 2 diabetes and is also associated with increased cardiovascular risk." | 2.41 | Insulin-sensitizing agents--thiazolidinediones (glitazones). ( Barnett, AH, 2002) |
| "Hyperglycemia is associated with increased risk of all-site cancer that may be mediated through activation of the renin-angiotensin-system (RAS) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase (HMGCR) pathways." | 1.40 | Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. ( Chan, JC; Cheung, KK; Chow, CC; Kong, AP; Lee, HM; Luk, A; Ma, RC; Ozaki, R; So, WY; Xu, G; Yang, X; Yu, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, VS | 1 |
| Vora, DK | 1 |
| Ramaa, CS | 1 |
| Veelen, A | 1 |
| Erazo-Tapia, E | 1 |
| Oscarsson, J | 1 |
| Schrauwen, P | 1 |
| Yasmin, S | 1 |
| Capone, F | 1 |
| Laghezza, A | 1 |
| Piaz, FD | 1 |
| Loiodice, F | 1 |
| Vijayan, V | 1 |
| Devadasan, V | 1 |
| Mondal, SK | 1 |
| Atlı, Ö | 1 |
| Baysal, M | 1 |
| Pattnaik, AK | 1 |
| Jayaprakash, V | 1 |
| Lavecchia, A | 1 |
| Kong, AP | 1 |
| Yang, X | 1 |
| So, WY | 1 |
| Luk, A | 1 |
| Ma, RC | 1 |
| Ozaki, R | 1 |
| Cheung, KK | 1 |
| Lee, HM | 1 |
| Yu, L | 1 |
| Xu, G | 1 |
| Chow, CC | 1 |
| Chan, JC | 1 |
| Song, YM | 1 |
| Hsu, HY | 1 |
| Chen, MD | 1 |
| Ojo, O | 1 |
| Säemann, MD | 1 |
| Krebs, M | 1 |
| Parchman, ML | 1 |
| Wang, CP | 1 |
| Rissanen, A | 1 |
| Howard, CP | 1 |
| Botha, J | 1 |
| Thuren, T | 1 |
| Rosenstock, J | 1 |
| Shen, SG | 1 |
| Gatlin, MR | 1 |
| Foley, JE | 1 |
| Barnett, AH | 1 |
| Kim, BY | 1 |
| Ahn, JB | 1 |
| Lee, HW | 1 |
| Moon, KS | 1 |
| Sim, TB | 1 |
| Shin, JS | 1 |
| Ahn, SK | 1 |
| Hong, CI | 1 |
| Kim, H | 1 |
| Haluzik, M | 1 |
| Gavrilova, O | 1 |
| Yakar, S | 1 |
| Portas, J | 1 |
| Sun, H | 1 |
| Pajvani, UB | 1 |
| Scherer, PE | 1 |
| LeRoith, D | 1 |
| Gross, JL | 1 |
| Smith, U | 1 |
| Rozenfeld, Y | 1 |
| Hunt, JS | 1 |
| Plauschinat, C | 1 |
| Wong, KS | 1 |
| Wolffenbuttel, BH | 1 |
| van Haeften, TW | 1 |
| Bailey, CJ | 1 |
| Castro Cabezas, M | 1 |
| Halkes, CJ | 1 |
| Erkelens, DW | 1 |
| Mahapatra, MK | 1 |
| Kumar, R | 1 |
| Kumar, M | 1 |
8 reviews available for 2,4-thiazolidinedione and Hyperglycemia
| Article | Year |
|---|---|
Thiazolidine-2,4-diones: progress towards multifarious applications.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumato | 2013 |
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Rece | 2021 |
The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
Topics: Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exenatide; Female; Glyc | 2016 |
Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?
Topics: Animals; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus; Humans; Hyperglycemia; Hypogly | 2010 |
Insulin-sensitizing agents--thiazolidinediones (glitazones).
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Europe; Hu | 2002 |
Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Topics: Acarbose; Aldehyde Reductase; Biguanides; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hy | 1995 |
Potential new treatments for type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insul | 2000 |
Obesity and free fatty acids: double trouble.
Topics: Chylomicrons; Coronary Artery Disease; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperlipid | 2001 |
2 trials available for 2,4-thiazolidinedione and Hyperglycemia
| Article | Year |
|---|---|
Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Glucose; D | 2012 |
Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated He | 2002 |
10 other studies available for 2,4-thiazolidinedione and Hyperglycemia
| Article | Year |
|---|---|
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.
Topics: Animals; Benzylidene Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease | 2017 |
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Hemoglobin A; Humans; Hydroxymethylglutar | 2014 |
Low dietary zinc intake attenuates the efficacy of 2,4-thiazolidinedione on reducing hyperglycemia in db/db mice (Short communication).
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Mice; M | 2015 |
Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c.
Topics: Acarbose; Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Electronic Health Records; F | 2012 |
Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives.
Topics: Animals; Cells, Cultured; Hepatocytes; Hyperglycemia; Hypoglycemic Agents; Male; Muscle Cells; Pyrro | 2003 |
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglyc | 2004 |
Inhaled insulin for diabetes mellitus.
Topics: Administration, Inhalation; Blood Glucose; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hyp | 2007 |
Introduction: Symposium on diabetes, inflammation and cardiovascular disease.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hyperglycemia; Hypoglycemic | 2007 |
Oral antidiabetic medication adherence and glycemic control in managed care.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; | 2008 |
Synthesis, biological evaluation and in silico studies of 5-(3-methoxybenzylidene)thiazolidine-2,4-dione analogues as PTP1B inhibitors.
Topics: Animals; Computer Simulation; Diabetes Mellitus; Drug Design; Enzyme Inhibitors; Humans; Hyperglycem | 2017 |